Treatment of Recurrent Eye Herpes Gladiatorum

Acute Treatment Regimen

The American Academy of Pediatrics recommends initiating combination therapy with both oral antiviral (valacyclovir 500 mg 2-3 times daily OR acyclovir 400 mg five times daily) AND topical antiviral (ganciclovir 0.15% gel 3-5 times daily) for recurrent eye herpes gladiatorum, as oral therapy alone is insufficient to prevent progression of corneal disease 1, 2
Valacyclovir 500 mg twice daily for 7 days is preferred for athletes due to better compliance with twice-daily dosing, according to the Pediatrics journal 3, 4
Ganciclovir 0.15% ophthalmic gel 3-5 times daily is preferred due to superior tolerability and less ocular surface toxicity 2

Treatment must be initiated within 24 hours of symptom onset to achieve maximum benefit, shortening HSV PCR clearance time by 21% (from ~8.1 days to 6.4 days), as recommended by the Pediatrics journal 3, 4
Topical corticosteroids are absolutely contraindicated in active epithelial disease as they potentiate viral replication and worsen infection, according to Praxis Medical Insights 2
Athletes must be isolated from competition for 3-8 days until all lesions are fully crusted, as recommended by the Pediatrics journal 3, 4

Schedule follow-up within 1 week, including visual acuity measurement and slit-lamp biomicroscopy, as recommended by Praxis Medical Insights 1, 2

Athletes may return to wrestling/contact sports only when all lesions are fully crusted (no active vesicles or ulcers), or a physician provides a written statement that the condition is non-infectious, as recommended by the Pediatrics journal 3, 4

Never use oral antivirals as monotherapy for active eye disease—topical therapy is essential for corneal disease control, according to Praxis Medical Insights 1, 2
Never prescribe corticosteroids for epithelial disease, even if inflammation appears significant, as recommended by Praxis Medical Insights 2
Topical acyclovir alone is substantially less effective than oral medication and should be avoided, according to the MMWR Recommendations and Reports 5, 6